LEAP-2: The Body's Natural Ghrelin Blocker Emerges as a Promising Anti-Obesity Target
LEAP-2, originally known as an antimicrobial peptide, is now recognized as the body's endogenous ghrelin receptor antagonist and inverse agonist, with circulating levels that inversely track ghrelin and correlate with energy status — making it a promising obesity therapeutic target.
Quick Facts
What This Study Found
LEAP-2 acts as both competitive ghrelin antagonist and inverse agonist of constitutive GHS-R1a activity. LEAP-2 increases with feeding/obesity, decreases with fasting/weight loss — inverse to ghrelin. LEAP-2/ghrelin molar ratio fluctuates with energy status and modulates food intake.
Key Numbers
LEAP-2: competitive antagonist + inverse agonist of GHS-R1a; increases with feeding/obesity; decreases with fasting/weight loss
How They Did This
Narrative review of LEAP-2 biology, GHS-R1a pharmacology, circulating LEAP-2/ghrelin dynamics, and metabolic effects. Discussion of LEAP-2 as therapeutic target for obesity.
Why This Research Matters
The body already has a natural hunger suppressor that counters ghrelin. Understanding and enhancing LEAP-2 signaling could provide a physiological, targeted approach to obesity treatment — working with the body's own appetite regulation rather than against it.
The Bigger Picture
LEAP-2 discovery transforms our understanding of appetite regulation from a single-hormone (ghrelin) model to a dual-hormone balance (ghrelin vs LEAP-2). This yin-yang system provides multiple intervention points for obesity therapy — boosting LEAP-2, blocking ghrelin, or both.
What This Study Doesn't Tell Us
Review article. LEAP-2 therapeutic applications are conceptual — no clinical trials yet. LEAP-2's effects on metabolic parameters beyond appetite need further study. The optimal LEAP-2/ghrelin ratio for weight management is unknown.
Questions This Raises
- ?Could LEAP-2 analogues be developed as anti-obesity drugs?
- ?Would LEAP-2 therapy complement GLP-1 drugs for additive weight loss?
- ?Does low LEAP-2 contribute to weight regain after dieting?
Trust & Context
- Key Stat:
- Nature's appetite off-switch LEAP-2 is the endogenous counterbalance to ghrelin — rising after meals to suppress hunger. Enhancing this natural system could provide physiological obesity treatment
- Evidence Grade:
- Not applicable (narrative review). Based on emerging basic science and preclinical evidence for LEAP-2's metabolic roles.
- Study Age:
- Published 2021. LEAP-2 research has accelerated with growing interest from pharmaceutical companies.
- Original Title:
- LEAP-2: An Emerging Endogenous Ghrelin Receptor Antagonist in the Pathophysiology of Obesity.
- Published In:
- Frontiers in endocrinology, 12, 717544 (2021)
- Authors:
- Lu, Xuehan, Huang, Lili, Huang, Zhengxiang, Feng, Dandan, Clark, Richard J, Chen, Chen
- Database ID:
- RPEP-05567
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is LEAP-2?
LEAP-2 (liver-expressed antimicrobial peptide 2) is a peptide produced by the liver that naturally blocks the ghrelin (hunger) receptor. It was originally thought to be just an immune peptide, but is now recognized as a key appetite regulator that rises after eating and falls during fasting.
Could boosting LEAP-2 help with weight loss?
Theoretically, yes. Since LEAP-2 naturally suppresses appetite by blocking ghrelin, enhancing its levels could reduce hunger. This is an early research concept — no LEAP-2 drugs are available yet, but it represents a promising target alongside GLP-1 drugs for obesity.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05567APA
Lu, Xuehan; Huang, Lili; Huang, Zhengxiang; Feng, Dandan; Clark, Richard J; Chen, Chen. (2021). LEAP-2: An Emerging Endogenous Ghrelin Receptor Antagonist in the Pathophysiology of Obesity.. Frontiers in endocrinology, 12, 717544. https://doi.org/10.3389/fendo.2021.717544
MLA
Lu, Xuehan, et al. "LEAP-2: An Emerging Endogenous Ghrelin Receptor Antagonist in the Pathophysiology of Obesity.." Frontiers in endocrinology, 2021. https://doi.org/10.3389/fendo.2021.717544
RethinkPeptides
RethinkPeptides Research Database. "LEAP-2: An Emerging Endogenous Ghrelin Receptor Antagonist i..." RPEP-05567. Retrieved from https://rethinkpeptides.com/research/lu-2021-leap2-an-emerging-endogenous
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.